Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells
Tóm tắt
The combination of cytarabine (ara-C) with fludarabine is a common approach to treating resistant acute myeloid leukemia. Success depends on a fludarabine triphosphate (F-ara-ATP)-mediated increase in the active intracellular metabolite of ara-C, ara-C 5’-triphosphate (ara-CTP). Therapy-resistant leukemia may exhibit ara-C resistance, the mechanisms of which might induce cross-resistance to fludarabine with reduced F-ara-ATP formation. The present study evaluated the effect of combining ara-C and fludarabine on ara-C-resistant leukemic cells in vitro. Two variant cell lines (R1 and R2) were 8-fold and 10-fold more ara-C resistant, respectively, than the parental HL-60 cells. Reduced deoxycytidine kinase activity was demonstrated in R1 and R2 cells, and R2 cells also showed an increase in cytosolic 5’-nucleotidase II activity. Compared with HL-60 cells, R1 and R2 cells produced smaller amounts of ara-CTP. Both variants accumulated less F-ara-ATP than HL-60 cells and showed cross-resistance to fludarabine nucleoside (F-ara-A). R2 cells, however, accumulated much smaller amounts of F-ara-ATP and were more F-ara-A resistant than R1 cells. In HL-60 and R1 cells, F-ara-A pretreatment followed by ara-C incubation produced F-ara-ATP concentrations sufficient for augmenting ara-CTP production, thereby enhancing ara-C cytotoxicity. No potentiation was observed in R2 cells. Nucleotidase might preferentially degrade F-ara-A monophosphate over ara-C monophosphate, leading to reduced F-ara-ATP production and thereby compromising the F-ara-A-mediated potentiation of ara-C cytotoxicity in R2 cells. Thus, F-ara-A-mediated enhancement of ara-C cytotoxicity depended on F-ara-ATP accumulation in ara-C-resistant leukemic cells but ultimately was associated with the mechanism of ara-C resistance.
Tài liệu tham khảo
Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clin Proc. 2006;81:247–260.
Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol. 2004;5:443–450.
Wiley JS, Jones SP, Sawyer WH, Paterson AR. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest. 1982;69:479–489.
Furth JJ, Cohen SS. Inhibition of mammalian DNA polymerase by the 5’-triphosphate of 1-β-D-arabinofuranosylcytosine and the 5’-triphosphate of 9-β-D-arabinofuranosyladenine. Cancer Res. 1968;28:2061–2067.
Inagaki A, Nakamura T, Wakisaka G. Studies on the mechanism of action of 1-β-D-arabinofuranosylcytosine as an inhibitor of DNA synthesis in human leukemic leukocytes. Cancer Res. 1969;29:2169–2176.
Graham FL, Whitmore GF.The effect of 1-β-D-arabinofuranosyl- cytosine on growth, viability, and DNA synthesis of mouse L-cells. Cancer Res. 1970;30:2627–2635.
Graham FL, Whitmore GF. Studies in mouse L-cells on the incorporation of 1-β-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-β-D-arabinofuranosylcytosine 5’-triphosphate. Cancer Res. 1970;30:2636–2644.
Kufe DW, Major PP, Egan EM, Beardsley GP. Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem. 1980;255:8997–9000.
Major PP, Egan EM, Beardsley GP, Minden MD, Kufe DW. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc Natl Acad Sci U S A. 1981;78:3235–3239.
Kufe D, Spriggs D, Egan EM, Munroe D. Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood. 1984;64:54–58.
Yamauchi T, Ueda T, Nakamura T. A new sensitive method for determination of intracellular 1-β-D-arabinofuranosylcytosine 5’-triphosphate content in human materials in vivo. Cancer Res. 1996;56:1800–1804.
Yamauchi T, Kishi S, Kawai Y, Ueda T. Pharmacokinetics of intracellular ara-CTP, an active metabolite of ara-C in leukemic cells from patients treated with ara-C including low-dose by a newly established assay [abstract]. Proc Am Soc Clin Oncol.1998;17:255a.
Yamauchi T, Ueda T. A sensitive new method for clinically monitoring cytarabine concentrations at the DNA level in leukemic cells. Biochem Pharmacol. 2005;69:1795–1803.
Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ. Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol. 1985;12(suppl 3):20–30.
Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988;48:329–334.
Gandhi V, Kemena A, Keating MJ, Plunkett W. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 1992;52:897–903.
Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11:116–124.
Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002;41:93–103.
Parker WB, Bapat AR, Shen JX, Townsend AJ, Cheng YC. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol. 1988;34:485–491.
Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony- stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 1994;12:671–678.
Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res. 1995;1:169–178.
Clavio M, Carrara P, Miglino M, et al. High efficacy of fludarabine- containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica. 1996;81:513–520.
Jackson G, Taylor P, Smith GM, et al. A multicentre, open, noncomparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol. 2001;112:127–137.
Steinmetz HT, Schulz A, Staib P, et al. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol. 1999;78:418–425.
Virchis A, Koh M, Rankin P, et al. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol. 2004;124:26–32.
Dumontet C, Fabianowska-Majewska K, Mantincic D, et al. Common 19. resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol. 1999;106:78–85.
Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia. 2001;15:875–890.
Jamieson GP, Snook MB, Wiley JS. Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells. Leuk Res. 1990;14:475–479.
Bai L, Yamaguchi M, Tatsumi M, Kon K, Brautigam M. Mechanisms responsible for resistance of sublines derived from leukemia cell lines to an antitumor agent 9-β-D-arabinofuranosyl-2- fluoroadenine. J Cancer Res Clin Oncol. 1998;124:367–373.
Mansson E, Flordal E, Liliemark J, et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol. 2003;65:237–247.
Yoshio N, Kawai Y, Hori H, Ueda T. Resistance to 9-α-D-arabino-furanosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues. Int J Hematol. 2005;81:405–412.
Jost LM, Kirkwood JM,Whiteside TL. Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods. 1992;147:153–165.
Yamauchi T, Ueda T. Simple and sensitive method for quantification of fludarabine triphosphate intracellular concentration in leukemic cells using isocratic liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;799:81–86.
Takemura H, Urasaki Y, Yoshida A, Fukushima T, Ueda T. Simultaneous treatment with 1-α-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells. Cancer Res. 2001;61:172–177.
Garrett C, Santi DV. A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts. Anal Biochem. 1979;99:268–273.
Mazzon C, Rampazzo C, Scaini MC, et al. Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy. Biochem Pharmacol. 2003;66:471–479.
Spychala J*, Madrid-Marina V, Fox IH. High Km soluble 5’-nucleotidase from human placenta: properties and allosteric regulation by IMP and ATP. J Biol Chem. 1988;263:18759–18765.
Gandhi V, Estey E, Du M, Keating MJ, Plunkett W. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofu- ranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res. 1997;3:1539–1545.
Galmarini CM, Graham K, Thomas X, et al. Expression of high Km 5’-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood. 2001;98:1922–1926.
Galmarini CM, Thomas X, Calvo F, et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol. 2002;117:860–868.
Schirmer M, Stegmann AP, Geisen F, Konwalinka G. Lack of crossresistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5’-nucleotidase activity. Exp Hematol. 1998;26:1223–1228.
Tseng WC, Derse D, Cheng YC, Brockman RW, Bennett LL Jr. In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol. 1982;21:474–477.